Stemline Therapeutics (NASDAQ:STML)

CAPS Rating: 3 out of 5

Caps

How do you think STML will perform against the market?

Add Stock to CAPS Watchlist

All Players

30 Outperform
4 Underperform
 

All-Star Players

11 Outperform
2 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top STML Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.80)
Submitted December 15, 2013

No stock better exemplifies the summer 2013 biopharma IPO bubble than Stemline. The stock peaked closed to 50 in October despite a lack of significant catalysts and has plunged along with the other 2013 IPO's. The current cap of 250M is much more… More

zzlangerhans (99.80)
Submitted August 04, 2013

Since I wasn't following biopharma during the amazing 2001 bubble, I can say that I've never seen higher valuations. If you want to get a more objective idea of what;s been going on in the sector of late, check out the long-term chart for the biotech… More

STML VS S&P 500 (SPY)

STML Summary

Recent Community Commentary

Read the most recent pitches from players about STML.

Recs

0
Member Avatar StockFrogger (64.44) Submitted: 3/24/2017 12:23:56 AM : Outperform Start Price: $8.50 STML Score: +70.53

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics. Stemline is developing three clinical stage product candidates, SL-401, SL-801, and SL-701 that target Cancer Stem Cells (CSC). Researchers have identified Cancer Stem Cells (CSCs) as the highly malignant "seeds" of tumors, typically comprising 1-5% of the tumor, that give rise to the majority (95-99%) of other tumor cells known as the "tumor bulk".

While standard therapies, including chemotherapy and radiation, may initially shrink tumors by killing tumor bulk, the failure of these therapies to eradicate CSCs may be a major contributor to treatment failure, tumor relapse and poor survival.

Accordingly, the company believes that new therapies designed to target CSCs, in addition to tumor bulk, may represent a major advance in the fight against cancer. This premise has formed the basis of their drug development strategy.

Buy with a target price of $12 and a three year target of $25.

Recs

2
Member Avatar zzlangerhans (99.80) Submitted: 12/15/2013 10:57:02 AM : Outperform Start Price: $20.32 STML Score: -72.75

No stock better exemplifies the summer 2013 biopharma IPO bubble than Stemline. The stock peaked closed to 50 in October despite a lack of significant catalysts and has plunged along with the other 2013 IPO's. The current cap of 250M is much more attractive for a narrowly focused biopharma headed into pivotal trials of a largely unproven therapy for a potentially lucrative indication. Lock-up expiration activity is likely resolved and hedge fund transactions have lately been favorable. If the momentum reverses once the pivotal trials kick off in early 2014, I might tag a small chunk of speculative capital onto Stemline for the ride.

Leaderboard

Find the members with the highest scoring picks in STML.

Score Leader

thebeef41

thebeef41 (58.82) Score: +126.56

The Score Leader is the player with the highest score across all their picks in STML.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
portefeuille 98.85 3/8/2016 Outperform 5Y $5.24 +203.43% +37.19% +166.24 0 Comment
thebeef41 58.82 10/1/2013 Underperform 3Y $45.53 -65.08% +61.48% +126.56 0 Comment
KidJones 29.63 8/13/2013 Underperform 5Y $35.75 -55.52% +61.58% +117.11 0 Comment
jack0071 74.21 7/18/2016 Outperform 5Y $7.04 +125.85% +26.46% +99.39 0 Comment
primetime300 98.40 11/18/2013 Underperform 5Y $21.99 -27.69% +51.43% +79.13 0 Comment
portefeuille4 99.74 9/2/2016 Outperform 5Y $8.05 +97.52% +25.23% +72.29 0 Comment
portefeuille2 99.45 9/2/2016 Outperform 5Y $8.13 +95.69% +24.98% +70.71 0 Comment
StockFrogger 64.44 3/24/2017 Outperform 1Y $8.50 +87.06% +16.52% +70.53 1 Comment
tenmiles 32.71 6/23/2017 Outperform 5Y $9.05 +75.69% +12.25% +63.44 0 Comment
tarikny500 < 20 8/1/2017 Outperform 5Y $9.30 +70.97% +10.37% +60.60 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for STML.

Featured Broker Partners